Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2010-04-19
2011-10-25
Navarro, Albert (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S418000, C435S252300, C424S239100
Reexamination Certificate
active
08044188
ABSTRACT:
The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.
REFERENCES:
patent: 5750383 (1998-05-01), Blissard et al.
patent: 5846929 (1998-12-01), Johnson et al.
patent: 6001806 (1999-12-01), Hilbert et al.
patent: 6022950 (2000-02-01), Murhpy
patent: 6323023 (2001-11-01), Shoseyov et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6852510 (2005-02-01), Bremel et al.
patent: 6967088 (2005-11-01), Williams et al.
patent: 7132259 (2006-11-01), Dolly et al.
patent: 7172764 (2007-02-01), Li et al.
patent: 7227010 (2007-06-01), Smith
patent: 7419676 (2008-09-01), Dolly et al.
patent: 7422877 (2008-09-01), Dolly et al.
patent: 7785606 (2010-08-01), Ichtchenko et al.
patent: 2001/0016199 (2001-08-01), Johnston et al.
patent: 2002/0107199 (2002-08-01), Walker
patent: 2002/0137886 (2002-09-01), Lin et al.
patent: 2003/0027752 (2003-02-01), Steward et al.
patent: 2003/0143651 (2003-07-01), Steward et al.
patent: 2003/0166238 (2003-09-01), Shone et al.
patent: 2003/0229454 (2003-12-01), Reinherz et al.
patent: 2004/0052819 (2004-03-01), Kingsley et al.
patent: 2004/0115215 (2004-06-01), Williams
patent: 2004/0220386 (2004-11-01), Steward et al.
patent: 2005/0060762 (2005-03-01), Bleck
patent: 2005/0106182 (2005-05-01), Li et al.
patent: 2005/0260230 (2005-11-01), Steward et al.
patent: 2006/0024794 (2006-02-01), Li et al.
patent: 2006/0039929 (2006-02-01), Fernandez-Salas et al.
patent: 2006/0204524 (2006-09-01), Ichtchenko et al.
patent: 2008/0057575 (2008-03-01), Fernandez-Salas et al.
patent: 0209281 (1987-01-01), None
patent: WO 98/07864 (1998-02-01), None
National Institute of Allergy and Infectious Diseases, “NIAID Biodefense Research Agenda for CDC Category A Agents. Progress Report,” NIH Publication # 03-5432, pp. 1-37 (2003).
Abrams, P., “The Role of Neuromodulation in the Management of Urinary Urge Incontinence,”BJU Int. 93(7):1116 (2004).
Achem, S.R., “Treatment of Spastic Esophageal Motility Disorders,”Gastroenterol Clin. North Am. 33(1):107-124 (2004).
Adler et al., “Botulinum Toxin Type A for Treating Voice Tremor,”Arch. Neurol. 61(9):1416-1420 (2004).
Agarwal et al., “Structural Analysis of Botulinum Neurotoxin Type E Catalytic Domain and Its Mutant Glu212→Gln Reveals the Pivotal Role of the Glu212 Carboxylate in the Catalytic Pathway,”Biochemistry43(21):6637-6644 (2004).
Aiin et al., “Botulinum Toxin for Masseter Reduction in Asian Patients,”Arch. Facial Plast. Surg. 6(3):188-191 (2004).
Aoki, K.R., “Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management,”Headache43(Suppl 1):S9-S15 (2003).
Aquilina et al., “Reduction of a Chronic Bilateral Temporomandibular Joint Dislocation with Intermaxillary Fixation and Botulinum Toxin A,”Br J. Oral Maxillofac. Surg. 42(3):272-273 (2004).
Bach-Rojecky & Lacković, “Antinociceptive Effect of Botulinum Toxin Type A in Rat Model of Carrageenan and Capsaicin Induced Pain,”Croat. Med. J. 46(2):201-208 (2005).
Bade et al., “Botulinum Neurotoxin Type D Enables Cytosolic Delivery of Enzymatically Active Cargo Proteins to Neurons via Unfolded Translocation Intermediates,”J. Neurochem. 91(6):1461-1472 (2004).
Bakheit, A.M., “Optimizing the Methods of Evaluation of the Effectiveness of Botulinum Toxin Treatment of Post-Stroke Muscle Spasticity,”J. Neurol. Neurosurg. Psychiatry75:665-666 (2004).
Balkrisiinan et al., “Longitudinal Examination of Health Outcomes Associated with Botulinum Toxin Use in Children with Cerebral Palsy,”J. Surg. Orthop. Adv. 13:76-80 (2004).
Bayles & Deschler, “Operative Prevention and Management of Voice-Limiting Pharyngoesophageal Spasm,”Otolaryngol Clin. North Am. 37(3):547-558 (2004).
Bender et al., “Speech Intelligibility in Severe Adductor Spasmodic Dysphonia,”J. Speech Lang. Hear. Res. 47(1):21-32 (2004).
Bentsianov et al., “Noncosmetic Uses of Botulinum Toxin,”Clin. Dermatol. 22(1):82-88 (2004).
Berweck & Heinen, “Use of Botulinum Toxin in Pediatric Spasticity (Cerebral Palsy),”Mov. Disord. 19(Suppl 8)S162-S167 (2004).
Blersch et al., “Botulinum Toxin A and the Cutaneous Nociception in Humans: A Prospective, Double-Blind, Placebo-Controlled, Randomized Study,”J. Neurol. Sci. 205(1):59-63 (2002).
Blumenfeld et al., “Botulinum Neurotoxin for the Treatment of Migraine and Other Primary Headache Disorders,”Dermatol. Clin. 22(2):167-175 (2004).
Brandt & Boker, “Botulinum Toxin for the Treatment of Neck Lines and Neck Bands,”Dermatol. Clin. 22(2):159-166 (2004).
Brisinda et al., “Botulinum Neurotoxin to Treat Chronic Anal Fissure: Results of a Randomized ‘Botox vs. Dysport’ Controlled Trial,”Aliment Pharmacol. Ther., 19(6):695-701 (2004).
Byrne et al., “Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain fromPichia pastorisas a Recombinant Vaccine Candidate,”Infect. Immun. 66(10):4817-4822 (1998).
Caccin et al., “VAMP/Synaptobrevin Cleavage by Tetanus and Botulinum Neurotoxins is Strongly Enhanced by Acidic Liposomes,”FEBS Lett. 542(1-3):132-136 (2003).
Capaccio et al., “Diagnosis and Therapeutic Management of Iatrogenic Parotid Sialocele,”Ann. Otol. Rhinol. Laryngol. 113(7):562-564 (2004).
Carruthers & Carruthers,“Botox: Beyond Wrinkles,”Clin. Dermatol. 22(1):89-93 (2004).
Carruthers & Carruthers, “Botulinum Toxin A in the Mid and Lower Face and Neck,”Dermatol. Clin. 22(2):151-158 (2004).
Carruthers & Carruthers, “Botulinum Toxin Type A for the Treatment of Glabellar Rhytides,”Dermatol. Clin. 22(2):137-144 (2004).
Chaddock et al., “Expression and Purification of Catalytically Active, Non-Toxic Endopeptidase Derivatives ofClostridium botulinumToxin Type A,”Protein Expr. Purif. 25(2):219-228 (2002).
Chaddock et al., “Retargeted Clostridial Endopeptidases: Inhibition of Nociceptive Neurotransmitter Release In Vitro, and Antinociceptive Activity in In Vivo Models of Pain,”Mov. Disord. 19(Suppl 8):S42-S47 (2004).
Chao et al., “Management of Pharyngoesophageal Spasm with Botox,”Otolaryngol Clin. North Am. 37(3):559-566 (2004).
Chen et al., “Altering Brow Contour with Botulinum Toxin,”Facial Plast. Surg. Clin. N. Am. 11:457-464 (2003).
Cruz, F., “Mechanisms Involved in New Therapies for Overactive Bladder,”Urology63(Suppl 3A):65-73 (2004).
Cui et al., “Subcutaneous Administration of Botulinum Toxin A Reduces Formalin-Induced Pain,”Pain107:(1-2):125-133 (2004).
Defazio & Livrea, “Primary Blepharospasm: Diagnosis and Management,”Drugs64(3):237-244 (2004).
Dekleva & DasGupta, “Nicking of Single ChainClostridium botulinumType A Neurotoxin by an Endogenous Protease,”Biochem. Biophys. Res. Commun. 162(2):767-772 (1989).
Derman et al., “Mutations That Allow Disulfide Bond Formation in the Cytoplasm ofEscherichia coli,” Science262(5140):1744-1747 (1993).
Dolly et al., “Accep
Band Philip A.
Ichtchenko Konstantin
LeClairRyan, a Professional Corporation
Navarro Albert
New York University
Portner Ginny
LandOfFree
Genetically engineered clostridial genes, proteins encoded... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically engineered clostridial genes, proteins encoded..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically engineered clostridial genes, proteins encoded... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286316